<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01451996</url>
  </required_header>
  <id_info>
    <org_study_id>16171A</org_study_id>
    <nct_id>NCT01451996</nct_id>
  </id_info>
  <brief_title>The Efficacy of Claritin in Healthy Subjects</brief_title>
  <official_title>The Efficacy of Claritin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this study is to examine determinants of the efficacy of Claritin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be given Claritin 10mg tablet. Subjects will be challenged with histamine via
      skin prick prior to Claritin administration and at 1 and 2 hours post administration. We will
      measure and record wheal and flare area 10 minutes following each challenge.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Wheal Reaction Area From Baseline --- 2 Hour</measure>
    <time_frame>baseline and 2 hours post administration of Claritin.</time_frame>
    <description>A research technician, blinded to the subject's condition, measured the extent of the skin inflammation at baseline and 2 hours post Claritin administration by tracing the wheal reaction after the histamine challenge (i.e. the slightly reddened, elevated area at the site of the challenge, a well-established measure of histamine response). The percentage change in the wheal reaction was calculated as the change (decrease) in the size relative to baseline, multiplied by 100. Wheal area was measured in mm^2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Wheal Reaction Area From Baseline --- 1 Hour</measure>
    <time_frame>baseline and 1 hours post administration of Claritin</time_frame>
    <description>A research technician, blinded to the subject's condition, measured the extent of the skin inflammation at baseline and 1 hour post Claritin administration by tracing the wheal reaction after the histamine challenge (i.e. the slightly reddened, elevated area at the site of the challenge, a well-established measure of histamine response). The percentage change in the wheal reaction was calculated as the change (decrease) in the size relative to baseline, multiplied by 100. Wheal area was measured in mm^2.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">340</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Claritin ads</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subject will be given 10mg Claritin tablet and then watch a movie that includes commercials for Claritin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zyrtec ads</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subject will be given 10mg Claritin tablet and then watch a movie that includes commercials for Zyrtec.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Claritin</intervention_name>
    <description>Subject will be given 10mg Claritin tablet.</description>
    <arm_group_label>Claritin ads</arm_group_label>
    <arm_group_label>Zyrtec ads</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria.

        1. Males and females between 18 and 65 years of age.

        Exclusion Criteria.

          1. Pregnant or lactating women.

          2. Upper respiratory infection within 14 days of study start.

          3. Women of childbearing potential not using specific contraception method(s) (i.e.,
             birth control pills, depo Provera, double barrier) as well as women who are
             breastfeeding.

          4. Patients with severe medical condition(s) that in the view of the investigator
             prohibits participation in the study (heart, lung, kidney, neurological, oncologic or
             liver disease).

          5. Use of any other investigational agent in the last 30 days.

          6. Use of medications that may affect skin testing. Specifically, subjects are excluded
             if they have used an antihistamine during the 4 days preceding their treatment visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anup Malani, J.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2011</study_first_submitted>
  <study_first_submitted_qc>October 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2011</study_first_posted>
  <results_first_submitted>January 18, 2018</results_first_submitted>
  <results_first_submitted_qc>March 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 13, 2018</results_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>direct-to-consumer advertising</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loratadine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Claritin Ads, Allergy+</title>
          <description>Subject, with positive skin test to at least one common allergen (grass, trees, mold, dust mites, ragweed, cats), will be given 10mg Claritin tablet and then watch a movie that includes commercials for Claritin.
Claritin: Subject will be given 10mg Claritin tablet.</description>
        </group>
        <group group_id="P2">
          <title>Zyrtec Ads, Allergy+</title>
          <description>Subject, with positive skin test to at least one common allergen (grass, trees, mold, dust mites, ragweed, cats), will be given 10mg Claritin tablet and then watch a movie that includes commercials for Zyrtec.
Claritin: Subject will be given 10mg Claritin tablet.</description>
        </group>
        <group group_id="P3">
          <title>Claritin Ads, Allergy-</title>
          <description>Subject, without allergies, will be given 10mg Claritin tablet and then watch a movie that includes commercials for Claritin.
Claritin: Subject will be given 10mg Claritin tablet.</description>
        </group>
        <group group_id="P4">
          <title>Zyrtec Ads, Allergy-</title>
          <description>Subject, without allergies, will be given 10mg Claritin tablet and then watch a movie that includes commercials for Zyrtec.
Claritin: Subject will be given 10mg Claritin tablet.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="87"/>
                <participants group_id="P3" count="85"/>
                <participants group_id="P4" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="87"/>
                <participants group_id="P3" count="85"/>
                <participants group_id="P4" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The sample was stratified into subjects with (Allergy+) and without (Allergy-) a positive skin test and block-randomized each subpopulation to the two advertisement conditions (Claritin ads and Zyrtec ads)</population>
      <group_list>
        <group group_id="B1">
          <title>Claritin Ads, Allergy+</title>
          <description>Subject, with positive skin test to at least one common allergen (grass, trees, mold, dust mites, ragweed, cats), will be given 10mg Claritin tablet and then watch a movie that includes commercials for Claritin.
Claritin: Subject will be given 10mg Claritin tablet.</description>
        </group>
        <group group_id="B2">
          <title>Zyrtec Ads, Allergy+</title>
          <description>Subject, with positive skin test to at least one common allergen (grass, trees, mold, dust mites, ragweed, cats), will be given 10mg Claritin tablet and then watch a movie that includes commercials for Zyrtec.
Claritin: Subject will be given 10mg Claritin tablet.</description>
        </group>
        <group group_id="B3">
          <title>Claritin Ads, Allergy-</title>
          <description>Subject, without allergies, will be given 10mg Claritin tablet and then watch a movie that includes commercials for Claritin.
Claritin: Subject will be given 10mg Claritin tablet.</description>
        </group>
        <group group_id="B4">
          <title>Zyrtec Ads, Allergy-</title>
          <description>Subject, without allergies, will be given 10mg Claritin tablet and then watch a movie that includes commercials for Zyrtec.
Claritin: Subject will be given 10mg Claritin tablet.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="83"/>
            <count group_id="B2" value="87"/>
            <count group_id="B3" value="85"/>
            <count group_id="B4" value="85"/>
            <count group_id="B5" value="340"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.83" lower_limit="18" upper_limit="65"/>
                    <measurement group_id="B2" value="29.30" lower_limit="18" upper_limit="65"/>
                    <measurement group_id="B3" value="27.25" lower_limit="18" upper_limit="65"/>
                    <measurement group_id="B4" value="26.40" lower_limit="18" upper_limit="65"/>
                    <measurement group_id="B5" value="27.70" lower_limit="18" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="59"/>
                    <measurement group_id="B5" value="212"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="63"/>
                    <measurement group_id="B5" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="85"/>
                    <measurement group_id="B5" value="340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Wheal Reaction Area From Baseline --- 2 Hour</title>
        <description>A research technician, blinded to the subject's condition, measured the extent of the skin inflammation at baseline and 2 hours post Claritin administration by tracing the wheal reaction after the histamine challenge (i.e. the slightly reddened, elevated area at the site of the challenge, a well-established measure of histamine response). The percentage change in the wheal reaction was calculated as the change (decrease) in the size relative to baseline, multiplied by 100. Wheal area was measured in mm^2.</description>
        <time_frame>baseline and 2 hours post administration of Claritin.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Claritin Ads, Allergy+</title>
            <description>Subject, with positive skin test to at least one common allergen (grass, trees, mold, dust mites, ragweed, cats), will be given 10mg Claritin tablet and then watch a movie that includes commercials for Claritin.
Claritin: Subject will be given 10mg Claritin tablet.</description>
          </group>
          <group group_id="O2">
            <title>Zyrtec Ads, Allergy+</title>
            <description>Subject, with positive skin test to at least one common allergen (grass, trees, mold, dust mites, ragweed, cats), will be given 10mg Claritin tablet and then watch a movie that includes commercials for Zyrtec.
Claritin: Subject will be given 10mg Claritin tablet.</description>
          </group>
          <group group_id="O3">
            <title>Claritin Ads, Allergy-</title>
            <description>Subject, without allergies, will be given 10mg Claritin tablet and then watch a movie that includes commercials for Claritin.
Claritin: Subject will be given 10mg Claritin tablet.</description>
          </group>
          <group group_id="O4">
            <title>Zyrtec Ads, Allergy-</title>
            <description>Subject, without allergies, will be given 10mg Claritin tablet and then watch a movie that includes commercials for Zyrtec.
Claritin: Subject will be given 10mg Claritin tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Wheal Reaction Area From Baseline --- 2 Hour</title>
          <description>A research technician, blinded to the subject's condition, measured the extent of the skin inflammation at baseline and 2 hours post Claritin administration by tracing the wheal reaction after the histamine challenge (i.e. the slightly reddened, elevated area at the site of the challenge, a well-established measure of histamine response). The percentage change in the wheal reaction was calculated as the change (decrease) in the size relative to baseline, multiplied by 100. Wheal area was measured in mm^2.</description>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" spread="2.5"/>
                    <measurement group_id="O2" value="29.0" spread="2.5"/>
                    <measurement group_id="O3" value="30.97" spread="2.4"/>
                    <measurement group_id="O4" value="25.0" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Wheal Reaction Area From Baseline --- 1 Hour</title>
        <description>A research technician, blinded to the subject's condition, measured the extent of the skin inflammation at baseline and 1 hour post Claritin administration by tracing the wheal reaction after the histamine challenge (i.e. the slightly reddened, elevated area at the site of the challenge, a well-established measure of histamine response). The percentage change in the wheal reaction was calculated as the change (decrease) in the size relative to baseline, multiplied by 100. Wheal area was measured in mm^2.</description>
        <time_frame>baseline and 1 hours post administration of Claritin</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Claritin Ads, Allergy+</title>
            <description>Subject, with positive skin test to at least one common allergen (grass, trees, mold, dust mites, ragweed, cats), will be given 10mg Claritin tablet and then watch a movie that includes commercials for Claritin.
Claritin: Subject will be given 10mg Claritin tablet.</description>
          </group>
          <group group_id="O2">
            <title>Zyrtec Ads, Allergy+</title>
            <description>Subject, with positive skin test to at least one common allergen (grass, trees, mold, dust mites, ragweed, cats), will be given 10mg Claritin tablet and then watch a movie that includes commercials for Zyrtec.
Claritin: Subject will be given 10mg Claritin tablet.</description>
          </group>
          <group group_id="O3">
            <title>Claritin Ads, Allergy-</title>
            <description>Subject, without allergies, will be given 10mg Claritin tablet and then watch a movie that includes commercials for Claritin.
Claritin: Subject will be given 10mg Claritin tablet.</description>
          </group>
          <group group_id="O4">
            <title>Zyrtec Ads, Allergy-</title>
            <description>Subject, without allergies, will be given 10mg Claritin tablet and then watch a movie that includes commercials for Zyrtec.
Claritin: Subject will be given 10mg Claritin tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Wheal Reaction Area From Baseline --- 1 Hour</title>
          <description>A research technician, blinded to the subject's condition, measured the extent of the skin inflammation at baseline and 1 hour post Claritin administration by tracing the wheal reaction after the histamine challenge (i.e. the slightly reddened, elevated area at the site of the challenge, a well-established measure of histamine response). The percentage change in the wheal reaction was calculated as the change (decrease) in the size relative to baseline, multiplied by 100. Wheal area was measured in mm^2.</description>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="2"/>
                    <measurement group_id="O2" value="17.5" spread="2.5"/>
                    <measurement group_id="O3" value="14.18" spread="3"/>
                    <measurement group_id="O4" value="10.83" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 hours post Claritin use</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Claritin Ads, Allergy+</title>
          <description>Subject, with positive skin test to at least one common allergen (grass, trees, mold, dust mites, ragweed, cats), will be given 10mg Claritin tablet and then watch a movie that includes commercials for Claritin.
Claritin: Subject will be given 10mg Claritin tablet.</description>
        </group>
        <group group_id="E2">
          <title>Zyrtec Ads, Allergy+</title>
          <description>Subject, with positive skin test to at least one common allergen (grass, trees, mold, dust mites, ragweed, cats), will be given 10mg Claritin tablet and then watch a movie that includes commercials for Zyrtec.
Claritin: Subject will be given 10mg Claritin tablet.</description>
        </group>
        <group group_id="E3">
          <title>Claritin Ads, Allergy-</title>
          <description>Subject, without allergies, will be given 10mg Claritin tablet and then watch a movie that includes commercials for Claritin.
Claritin: Subject will be given 10mg Claritin tablet.</description>
        </group>
        <group group_id="E4">
          <title>Zyrtec Ads, Allergy-</title>
          <description>Subject, without allergies, will be given 10mg Claritin tablet and then watch a movie that includes commercials for Zyrtec.
Claritin: Subject will be given 10mg Claritin tablet.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anup Malani, J.D., Ph.D</name_or_title>
      <organization>University of Chicago</organization>
      <phone>773-702-9602</phone>
      <email>amalani@uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

